OncoSil Medical secures TGA approval for pancreatic cancer device

OncoSil Medical has secured the Australian TGA approval for its OncoSil device, permitting its use in the treatment of LAPC alongside gemcitabine-based chemotherapy. The approval is expected to drive increased clinical adoption and support applications for regulatory approval in other markets. The approval supports further regulatory submissions internationally. Credit: SofikoS / Shutterstock.com. OncoSil Medical has secured the Australian Therapeutic Goods Administration (TGA) approval for its OncoSil device, permitting its use in the treatment of locally advanced pancreatic cancer (LAPC) alongside gemcitabine-based chemotherapy. The TGA’s decision enables the device’s entry onto the Australian Register of Therapeutic Goods (ARTG), allowing access to…

Source: Medical Device Network